By Stephan Lutzmayer, Consultant, EMEA Thought Leadership, IQVIA
Years after the COVID-19 outbreak, the medical industry is still battling the logistical challenges of delivering vaccines globally. This is mostly related to the scaling up of the refrigerated networks that make up part of the global “cold chain” — the uninterrupted process of maintaining end-to-end temperature-controlled conditions from the manufacturing site to the point of care.
Unlike ambient temperature medicines, cold chain drugs require more energy and care to ensure a successful delivery that doesn’t spoil the product. If pharmaceutical companies want to live up to their ambitious environmental, social, and governance (ESG) targets, they will need to understand current and future trends and work closely with logistics companies to ensure delivery of often live-saving cold chain medicines whilst having their CO2 footprint in mind.
Delve into a data-driven approach to assess the volume and value of cold chain medicines by combining IQVIA audit data with publicly available data.